MAGEA11 and prostate carcinoma: MAGE-A11 has a low expression level in normal human testis, ovary, and placenta, while it is upregulated during prostate cancer progression due to hypomethylation of the MAGE-A11 promoter and increasing cyclic AMP levels, associated with increased AR transcriptional activity 11, 12.